Department of Surgery, Austin Health, University of Melbourne, Victoria, Australia.
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Eur Urol Oncol. 2023 Feb;6(1):4-15. doi: 10.1016/j.euo.2022.09.001. Epub 2022 Sep 23.
Active surveillance (AS) represents the preferred treatment option in patients with low-risk prostate cancer. Optimised patient selection has enabled more patients to be managed with AS for a longer time. Thus, there is growing interest in its effect on long-term quality of life compared with interventional management.
To perform a systematic review evaluating the long-term patient-reported outcomes regarding mental health, and sexual and urinary function in patients on AS.
We performed a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. We included series assessing validated patient-reported outcomes of health-related quality of life, and sexual and urinary function in AS patients followed up for at least 5 yr.
Our search yielded 1854 citations, including 19 papers involving 3643 patients on AS, 14 651 patients receiving surgery or radiotherapy, and 2478 controls without prostate cancer. In ten studies, major differences were observed in sexual and urinary symptoms between groups, such as better sexual function and fewer irritative urinary symptoms in patients on AS, though overall functional outcomes were comparable. In all studies, health-related quality of life for patients on AS was better than, or similar to, that for patients who had undergone surgery or radiotherapy and comparable with that for individuals without cancer.
We observed differences in specific functional outcomes between patients on AS and surgery or radiotherapy, ≥5 yr after treatment. Patients on AS reported good quality of life, similar to that in individuals without prostate cancer. AS should continue to be a recommended management strategy for appropriately selected patients.
Active surveillance is an accepted pathway for patients with low-risk localised prostate cancer. Previous literature has shown that it did not negatively affect short-term quality of life. This review finds that long-term quality of life for these patients is similar to that for people without prostate cancer.
主动监测(AS)是低危前列腺癌患者的首选治疗方案。通过优化患者选择,使更多的患者能够接受 AS 治疗,并延长治疗时间。因此,人们越来越关注 AS 对长期生活质量的影响,而不是干预性治疗。
系统评价 AS 对患者心理健康以及性功能和尿控功能的长期影响。
我们按照系统评价和荟萃分析的首选报告项目进行了系统评价。我们纳入了评估 AS 患者至少 5 年随访时健康相关生活质量的患者报告结局的系列研究,包括性功能和尿控功能。
我们的检索结果共得到 1854 条引用,其中包括 19 篇论文,涉及 3643 例接受 AS 治疗的患者、14651 例接受手术或放疗的患者和 2478 例无前列腺癌的对照组。在 10 项研究中,两组之间在性功能和尿控症状方面存在明显差异,如 AS 组患者的性功能更好,刺激性尿症状更少,尽管总体功能结局相当。在所有研究中,AS 组患者的健康相关生活质量均优于或与接受手术或放疗的患者相似,与无癌症个体相当。
我们观察到治疗后 5 年以上,AS 组与手术或放疗组之间在特定功能结局方面存在差异。AS 组患者报告生活质量良好,与无前列腺癌个体相似。AS 应继续作为适当选择患者的推荐治疗策略。
AS 是低危局限性前列腺癌患者的一种可接受的治疗途径。先前的文献表明,它不会对短期生活质量产生负面影响。本综述发现,这些患者的长期生活质量与没有前列腺癌的人相似。